companies

Pear Bio

Founded 2018
Employees 20+
Primary contact
Camburgh House
27 New Dover Road, Kent
CT1 3DN Cantenbury
United Kingdom
Links
https://www.pearbio.com/
Diseases & Conditions
Sections
Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. The company is building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Pear Bio's technology is applicable across solid tumors, and it is currently working on a pipeline of biomarker-negative cancers, with triple-negative breast cancer as the lead indication.
Founded 2018
Employees 20+
Primary contact
Camburgh House
27 New Dover Road, Kent
CT1 3DN Cantenbury
United Kingdom
Links
https://www.pearbio.com/
Diseases & Conditions
Sections

Funding 💰

Total $19.8M
Last round 🔗 $14M
Series A
May 15, 2023.
Select investors Octopus Ventures, Greater London Authority, Hoxton Ventures, SOSV, Crista Galli Ventures, Compound, Fly Ventures

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Multiple applications: The company's technology has three main applications: personalized cancer medicine (helping doctors eliminate FDA-approved cancer regimens that aren't effective for a particular patient), clinical trials (matching suitable patients with experimental drugs), and pharma R&D (helping pharma companies discover biomarkers and patient populations for new drug development).
  • Faster than competitors: According to Pear Bio's CEO, they have a faster process, returning test results in less than a week compared to the 10 days that competing firms needs. Once at clinical application stage, this time saved could be vital for a cancer patient's chance of successfully responding to treatment. 🔗
  • Solid team: Pear Bio's team has experience in big pharma and R&D tools, and its medical advisory board includes oncologists from MD Anderson, Imperial College London, Stanford University Medical Center and UCSF.

Video ▶️

In the news 📰

Pear Bio secures $14M Series A to improve the efficacy of cancer drugs
May 16, 2023

Awards & Recognitions 🏆

  • 2022 UK Business Angels Association awards: Hard Tech Investment of the Year Award
Last update: May 16, 2023